ITCI Insider Trading

Insider Ownership Percentage: 2.60%
Insider Buying (Last 12 Months): $0.00
Insider Selling (Last 12 Months): $49,905,719.27

Intra-Cellular Therapies Insider Trading History Chart

This chart shows the insider buying and selling history at Intra-Cellular Therapies by year and by quarter.

Skip ChartChart Data in Insider Trading History Table
2021202220232024$0bought$6.41MsoldQ4Q1Q2Q3Q4Q1Q2Q3Q4Q1Q2Q3Q4-$20M$0$20MTotal Insider BuyingTotal Insider Selling

Intra-Cellular Therapies Share Price & Price History

Current Price: $85.19
Price Change: Price Decrease of -1.53 (-1.76%)
As of 12/19/2024 11:50 AM ET

This chart shows the closing price history over time for ITCI up to the past year.

Skip Chart and Table DataPrice Data in Insider Trading History Table
Days: 30 | 90 | 365
JanFebMarAprMayJunJulAugSepOctNovDec$86.72Closing price on 12/18/24:

SEC Filings (Institutional Ownership Changes) for Intra-Cellular Therapies (NASDAQ:ITCI)

92.33% of Intra-Cellular Therapies stock is owned by institutions. Institutional ownership can be a sign of analyst confidence in the fundamentals of the stock.

Institutional Buying and Selling by Quarter

This chart shows the instiutional buying and selling at ITCI by year and by quarter.

Skip Institutional Buying and Selling Chart and Table DataRead Chart Data in Institutional Trading History Table
2021202220232024$150Mbought$169MsoldQ4Q1Q2Q3Q4Q1Q2Q3Q4Q1Q2Q3Q4-$400M-$200M$0$200M$400MTotal InflowsTotal Outflows
Intra-Cellular Therapies logo
Intra-Cellular Therapies, Inc., a biopharmaceutical company, focuses on the discovery, clinical development, and commercialization of small molecule drugs that address medical needs primarily in neuropsychiatric and neurological disorders by targeting intracellular signaling mechanisms in the central nervous system (CNS) in the United States. The company offers CAPLYTA for the treatment of schizophrenia and bipolar depression in adults. It is also involved in developing Lumateperone, which is in Phase 3 clinical trial for the treatment of various depressive disorders, as well as additional neuropsychiatric indications. In addition, the company is developing Lenrispodun (ITI-214) for the treatment of Parkinson's disease, CNS, and other disorders; ITI-1284 for the treatment of neuropsychiatric disorders and behavioral disturbances in dementia; and ITI-333 for substance use disorders, pain, and psychiatric comorbidities, including depression, anxiety, and sleep disorders. Intra-Cellular Therapies, Inc. was founded in 2002 and is headquartered in New York, New York.
Read More on Intra-Cellular Therapies

Today's Range

Now: $85.19
Low: $84.29
High: $87.95

50 Day Range

MA: $83.28
Low: $73.61
High: $91.57

52 Week Range

Now: $85.19
Low: $62.78
High: $93.45

Volume

158,182 shs

Average Volume

823,917 shs

Market Capitalization

$9.03 billion

P/E Ratio

N/A

Dividend Yield

N/A

Beta

0.95

Who are the company insiders with the largest holdings of Intra-Cellular Therapies?

Intra-Cellular Therapies' top insider shareholders include:
  1. Sharon Mates (CEO)
  2. Rory B Riggs (Director)
  3. Mark Neumann (EVP)
  4. Joel S Marcus (Director)
  5. Lawrence J Hineline (CFO)
  6. Michael Halstead (EVP)
  7. Suresh K Durgam (EVP)
  8. Suresh K Durgam (SVP)
  9. Nostrand Robert L Van (Director)
  10. Michael Halstead (President)
  11. Suresh K Durgam (EVP)
Learn More about top insider investors at Intra-Cellular Therapies.

Who are the major institutional investors of Intra-Cellular Therapies?

Intra-Cellular Therapies' top institutional shareholders include:
  1. FMR LLC — 10.49%
  2. Wasatch Advisors LP — 3.63%
  3. Bellevue Group AG — 2.34%
  4. State Street Corp — 1.75%
  5. Franklin Resources Inc. — 1.65%
  6. Geode Capital Management LLC — 1.61%
Learn More about top institutional investors of Intra-Cellular Therapies stock.

Which institutional investors are selling Intra-Cellular Therapies stock?

In the previous quarter, ITCI stock was sold by these institutional investors:
  1. Point72 Asset Management L.P.
  2. Wellington Management Group LLP
  3. Bank of Montreal Can
  4. Suvretta Capital Management LLC
  5. FMR LLC
  6. Assenagon Asset Management S.A.
  7. Holocene Advisors LP
  8. PFM Health Sciences LP
During the last year, company insiders that have sold Intra-Cellular Therapies company stock include:
  1. Sharon Mates (CEO)
  2. Rory B Riggs (Director)
  3. Mark Neumann (EVP)
  4. Joel S Marcus (Director)
  5. Lawrence J Hineline (CFO)
  6. Michael Halstead (EVP)
  7. Suresh K Durgam (EVP)
  8. Suresh K Durgam (SVP)
  9. Nostrand Robert L Van (Director)
  10. Michael Halstead (President)
Learn More investors selling Intra-Cellular Therapies stock.

Which institutional investors are buying Intra-Cellular Therapies stock?

During the last quarter, ITCI stock was acquired by institutional investors including:
  1. Eagle Asset Management Inc.
  2. Franklin Resources Inc.
  3. Wasatch Advisors LP
  4. M&G PLC
  5. Westfield Capital Management Co. LP
  6. BNP PARIBAS ASSET MANAGEMENT Holding S.A.
  7. State Street Corp
  8. Parkman Healthcare Partners LLC